Stockscreener 앱 받기
24.25
1.78%
-0.44
시간 외 거래:
24.39
0.14
+0.58%
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - Insider Monkey
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - simplywall.st
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World
Where are the Opportunities in (CPRX) - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India
Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
When and Where to Hear Catalyst Pharmaceuticals' Future Plans: CEO Set for Major Healthcare Conference - StockTitan
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $32.00 at Robert W. Baird - Defense World
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges - Seeking Alpha
Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Strong-Buy at StockNews.com - Defense World
Sanctuary Advisors LLC Has $1.24 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - MSN
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap UpHere's What Happened - MarketBeat
Catalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating - Marketscreener.com
Ieq Capital LLC Invests $313,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Principal Financial Group Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Reports Record 2024 Financial Results - TipRanks
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Quarterly Earnings Results - MarketBeat
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today - MSN
1.05%
1.79%
자본화:
|
볼륨(24시간):